NCT05704985View on ClinicalTrials.gov

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

April 3, 2023

Primary Completion Date

July 31, 2025

Study Completion Date

October 31, 2025

Conditions
CancerSolid TumorColorectal CancerPancreas CancerNon Small Cell Lung CancerHead and Neck CancerGynecologic CancerSkin CancerKidney Cancer
Interventions
BIOLOGICAL

DK210 (EGFR)

Solution for SC administration

RADIATION

Radiation therapy

Short regimen radiation therapy (10 fractions or less)

BIOLOGICAL

Immune checkpoint blockers

IV administration of approved PD1 blocker

DRUG

Chemotherapy

Single agent or combination of not more than two

Trial Locations (7)

11030

Northwell Health, Manhasset

22031

NEXT Oncology, Fairfax

73104

OU Health Stephenson Cancer Center, Oklahoma City

75230

Mary Crowley Cancer Research, Dallas

75390

University of Texas Southwestern, Dallas

77030

The University of Texas M.D. Anderson Cancer Center, Houston

91010

City of Hope, Duarte

Sponsors

Lead Sponsor

DEKA Biosciences
All Listed Sponsors
lead

DEKA Biosciences

INDUSTRY